This trial is active, not recruiting.

Condition prostate cancer
Treatment mr-guided transurethral us ablation of prostate tissue
Phase phase 1
Sponsor Profound Medical Inc.
Start date March 2013
End date March 2014
Trial size 30 participants
Trial identifier NCT01686958, PMI-10246


This study is to evaluate that the MRI-guided transurethral ultrasound therapy system is safe and feasible to ablate prostate tissue in men with localized prostate cancer.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
MR-Guided Transurethral US Ablation of Prostate Tissue
mr-guided transurethral us ablation of prostate tissue Prostate Ablation Device: PAD-105
The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.

Primary Outcomes

Evaluate the frequency and severity of device / treatment related adverse events associated with the use of the investigational system to coagulate prostate tissue.
time frame: 12 months from the Treatment Date

Secondary Outcomes

Evaluate the effectiveness of the investigation system to thermally coagulate prostate tissue conforming to the target volume with a high degree of accuracy and precision.
time frame: 12 months from the Treatment Date

Eligibility Criteria

Male participants from 65 years up to 75 years old.

Inclusion Criteria: - Male, age ≥65 - Patient with low-risk, early-stage organ-confined prostate cancer (Stage T1c or T2a, N0, M0). - Gleason score 6 (3+3) - PSA ≤ 10 ng/ml - Eligible for MR imaging (DOC-10252) - Meets the following criteria on pre-treatment transrectal ultrasound imaging: 1. No cysts or calcifications > 1.0 cm in size 2. No evidence of extraprostatic extension or seminal vesicle invasion 3. Overall prostate size less than 5 cm in sagittal length and less than 7 cm in diameter - Biopsy confirmed adenocarcinoma of the prostate, performed at least 6 weeks prior to and no more than 6 months prior to the scheduled treatment. - Eligible for General Anesthesia, as defined in American Society of Anesthesiologists (ASA) - Normal rectal anatomy and rectal mucosa on digital rectal examination Exclusion Criteria: - Bleeding disorder - Abnormal coagulation and current anticoagulant therapy. - Acute or chronic Urinary Tract Infection - Interest in future fertility - History of allergy relevant medication or other - History of any other malignancy other than skin cancer - Patients with peripheral arterial disease with intermittent claudication or Leriches Syndrome - Prior treatment of the prostate gland - Prior treatment with 5 alpha reductase inhibitor allowed (not as prostate cancer treatment or prevention) as long as drug has been stopped for minimum 3 months - History of any major rectal or pelvic surgery - History of ulcerative colitis or other chronic inflammatory conditions affecting rectum - History of documented clinical prostatitis requiring therapy within previous 6 months - History of urethral and bladder outlet disorders, including urethral stricture disease, urethral diverticulae, bladder neck contracture, urethral fistulae which had required prior urethrotomy, urethral stenting, urethroplasty or chronic indwelling urethral catheter - Patients with artificial urinary sphincter or any penile implant (metallic or non-metallic) - Neurologic bladder disorders - Untreated bladder stones - History of acute urinary retention - Confirmed or suspected bladder cancer - Urinary sphincter abnormalities - Active untreated gross hematuria for any cause - Post Void Residual (PVR) bladder volume > 250 mL - Obstructing median lobe enlarged out of proportion to the rest of the prostate and protruding significantly into the bladder Additional exclusion criteria on file....

Additional Information

Official title Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer
Principal investigator Joseph Chin, MD
Description Profound Medical Inc. has developed a novel technology called the MRI-guided transurethral ultrasound therapy system. The technology is developed for patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue. The treatment is conducted completely within an MRI suite, which enables real-time temperature images of the heated region to be acquired as the ultrasonic treatment is delivered. Using MRI thermometry during treatment, dynamic temperature feedback control over the intensity of the ultrasound beams and rotation of the Ultrasound Applicator can shape the pattern of thermal coagulation accurately and precisely in the prostate gland, thereby reducing the risk of possible damage to important surrounding anatomy such as the rectum, urinary sphincters, neurovascular bundles and pelvic bone. This coagulation method, therefore, has the potential to have lower complication rates than conventional therapies.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Profound Medical Inc..